According to the U.S. Centers for Disease Control and Prevention (CDC), influenza activity remained low nationally in the week ending October 10, 2026, but several indicators had been increasing since late August and early September.

The percentage of clinical laboratory specimens testing positive for influenza rose from 3.9% in the previous week to 5.0%. Although these figures do not indicate how severe the full season will be, they demonstrate why respiratory virus surveillance and diagnostic readiness matter early in the season.

The World Health Organization (WHO) estimates that seasonal influenza causes approximately one billion infections worldwide each year, including 3–5 million cases of severe illness. These long-term estimates underline the continuing global burden of influenza, even though the timing and severity of each season vary.

As a medical device manufacturer specializing in specimen collection and transport products, Huachenyang (HCY)provides solutions for healthcare and laboratory applications, including flocked swabs and viral transport medium (VTM).

For diagnostic laboratories, healthcare providers, and medical device distributors, selecting compatible collection materials and maintaining standardized handling procedures can help support a consistent respiratory testing workflow throughout flu season.

As influenza activity evolves during the 2026–2027 season, preparation begins with reliable surveillance, appropriate testing, and careful attention to every step from specimen collection to laboratory analysis.